A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals

First Beijing Investment Ltd disclosed a new position in Legend Biotech (NASDAQ:LEGN), acquiring 2,296,335 shares in the first quarter, with the estimated trade valued at $43.78 million based on average quarterly pricing, according to a May 13, 2026, SEC filing.Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.According to an SEC filing dated May 13, 2026, First Beijing Investment Ltd established a new stake in Legend Biotech, purchasing 2,296,335 shares. The estimated transaction value was $43.78 million, calculated using the average closing price for the first quarter. The quarter-end value of this position stood at $41.54 million, reflecting both purchase activity and share price movement during the period.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool